ÐÂÎÅÖÐÐÄ
News Center
bevictorΰµÂ¹ÙÍø - ΤµÂ¹Ù·½ÍøÕ¾1ÀàÁ¢ÒìÒ©ÂÞ·¥ÎôÌæÄáƬҪº¦×¢²áÑо¿È¡µÃÑôÐÔЧ¹û
Ðû²¼Ê±¼ä£º2024-04-19
¿ËÈÕ£¬ £¬£¬£¬£¬bevictorΰµÂ¹ÙÍø - ΤµÂ¹Ù·½ÍøÕ¾£¨1177.HK£©ÏÂÊôÆóÒµÕý´óÌìÇçÒ©Òµ×ÔÖ÷Ñз¢µÄ1ÀàÁ¢ÒìÒ©ÂÞ·¥ÎôÌæÄáƬ£¨Rovadicitinib £¬ £¬£¬£¬£¬TQ05105£©ÓÃÓÚÖÎÁÆÖиßΣ¹ÇËèÏËά»¯ (MF) µÄÒªº¦×¢²áÁÙ´²Ñо¿ÒѵִïÖ÷ÒªÖյ㡣¡£¡£ ¡£¡£Õý´óÌìÇçÒÑÓëÖйú¹ú¼ÒÒ©Æ·¼àÊÓÖÎÀí¾ÖÒ©Æ·ÉóÆÀÖÐÐÄ (CDE) ¾ÍTQ05105ƬµÄÉÏÊÐÉêÇë¾ÙÐÐÁËÏàͬ£¬ £¬£¬£¬£¬²¢»ñµÃCDEÔÞ³ÉÌá½»±¾Æ·ÉÏÊÐÉêÇëµÄÒâ¼û¡£¡£¡£ ¡£¡£Õý´óÌìÇ罫ÓÚ½üÆڵݽ»TQ05105ƬµÄÉÏÊÐÉêÇë¡£¡£¡£ ¡£¡£
TQ05105ÊDZ¾¼¯ÍÅ×ÔÖ÷Ñз¢µÄÒ»¿î¾ßÓÐȫл¯Ñ§½á¹¹µÄJAK/ROCKÒÖÖƼÁ¡£¡£¡£ ¡£¡£ÌåÍâÊÔÑéЧ¹ûÏÔʾ£¬ £¬£¬£¬£¬TQ05105Äܹ»ÓÐÓÃÒÖÖÆJAK¼Ò×弤ø»îÐÔ¼°ROCK¼¤Ã¸»îÐÔ£¬ £¬£¬£¬£¬ÄÜÏÔÖøÒÖÖÆϸ°ûÖÐSTAT3ºÍSTAT5µÄÁ×Ëữˮƽ£¬ £¬£¬£¬£¬´Ó¶øÒÖÖÆJAK/STATÐźÅͨ·´«µ¼×÷Ó㬠£¬£¬£¬£¬½ø¶øÊ©Õ¹¿¹Ö×Áö»îÐÔ¡£¡£¡£ ¡£¡£
±¾¼¯ÍÅÓÚ2023ÄêÃÀ¹úѪҺѧÄê»á (ASH) Ðû²¼ÁËTQ05105ÓÃÓÚÖÎÁƹÇËèÔöÖ³ÐÔÖ×Áö (MPN)µÄIÆÚÁÙ´²Ñо¿Êý¾Ý[1]¡£¡£¡£ ¡£¡£Ð§¹ûÅú×¢£¬ £¬£¬£¬£¬TQ05105¾ßÓÐÓÅÒìµÄÈËÌåÒ©´ú¶¯Á¦Ñ§ÐÐΪ£¬ £¬£¬£¬£¬¶¾ÐÔ¿ÉÄÍÊÜ£¬ £¬£¬£¬£¬×î¼ÑËõÆ¢ÂÊ63.79%£¬ £¬£¬£¬£¬ÌåÖÊÖ¢×´×î¼Ñ¸ÄÉÆÂÊΪ87.50%£¬ £¬£¬£¬£¬ÓÐÍûΪMF»¼Õß´øÀ´¸ü¶àµÄÁÙ´²Ñ¡Ôñ¡£¡£¡£ ¡£¡£
±ðµÄ£¬ £¬£¬£¬£¬±¾¼¯ÍÅÓÚ2023ÄêÅ·ÖÞѪҺѧÄê»á (EHA) Ðû²¼ÁËTQ05105ÔÚÂýÐÔÒÆÖ²ÎËÞÖ÷²¡(cGVHD) ÖеÄIb/IIÆÚÁÙ´²Ñо¿Êý¾Ý[2]¡£¡£¡£ ¡£¡£Ð§¹ûÅú×¢£¬ £¬£¬£¬£¬TQ05105ÔÚcGVHD»¼ÕßÖУ¬ £¬£¬£¬£¬¶¾ÐÔ¿ÉÄÍÊÜ£¬ £¬£¬£¬£¬¶Ô¸÷ÅÅÒìÆ÷¹Ù²¿Î»×î¼Ñ¿Í¹Û»º½âÂÊ 86.7%£¬ £¬£¬£¬£¬40%»¼ÕßLSSÆÀ·Ö¸ÄÉÆ≥7·Ö£¬ £¬£¬£¬£¬73.3%»¼Õß½µµÍ¼¤ËØʹÓüÁÁ¿£¬ £¬£¬£¬£¬ÓÐÍûΪcGVHD»¼Õß´øÀ´¸ü¶àµÄÁÙ´²ÖÎÁÆÑ¡Ôñ¡£¡£¡£ ¡£¡£
MFÊÇÒ»ÖÖÃÖÂþÐÔ¹ÇËèÏËά×éÖ¯ÔöÉúÐÔ¼²²¡£¡£¡£ ¡£¡£¬ £¬£¬£¬£¬ÊôÓÚMPNµÄÒ»ÖÖ£¬ £¬£¬£¬£¬×îÖÕ»áÏ£ÍûΪ¹ÇËèË¥½ß»òת»¯Îª¼±ÐÔ°×Ѫ²¡¡£¡£¡£ ¡£¡£2023Äê9Ô£¬ £¬£¬£¬£¬Ô·¢ÐÔ¹ÇËèÏËά»¯ (PMF) ±»ÄÉÈëÖйú¡¶µÚ¶þÅúÓÐÊý²¡Ä¿Â¼¡·¡£¡£¡£ ¡£¡£ÏÖÔÚ£¬ £¬£¬£¬£¬º£ÄÚ½öÓЫ¿ÉÌæÄá»ñÅúÓÃÓÚMF»¼ÕßµÄÖÎÁÆ[3]£¬ £¬£¬£¬£¬ÁÙ´²±£´æ½Ï´óδ±»Öª×ãµÄÐèÇ󡣡£¡£ ¡£¡£
±¾¼¯ÍÅÔÚ¹ÇËèÏËά»¯ÁìÓò»¹½á¹¹Á˶àÏîÍŽáÑо¿£¬ £¬£¬£¬£¬ÈçTQ05105ÍŽáBETÒÖÖƼÁ»òBCL-2ÒÖÖƼÁ£¬ £¬£¬£¬£¬ÓÃÓÚÖÎÁÆÖиßΣ¹ÇËèÏËά»¯µÄÁÙ´²Ñо¿£¬ £¬£¬£¬£¬ÆðԴЧ¹û½ÏΪÆ𾢡£¡£¡£ ¡£¡£TQ05105ÊDZ¾¼¯Íż´½«É걨ÉÏÊеÄÓÖÒ»¿î1ÀàÁ¢ÒìÒ©¡£¡£¡£ ¡£¡£Ëæ×ű¾¼¯ÍÅÔÚÁ¢ÒìÒ©Ñз¢ÖеÄһֱͶÈ룬 £¬£¬£¬£¬Á¢Òì²úÆ·È¡µÃһֱͻÆÆ£¬ £¬£¬£¬£¬Á¢Òì¹ÜÏßÒѽøÈëÊÕ»ñÆÚ¡£¡£¡£ ¡£¡£
×ÊÁÏȪԴ£º
[1] Zefeng Xu, Ling Pan, Zhenya Hong,et al; First-in-Class JAK/Rock Inhibitor Rovadicitinib in Myeloproliferative Neoplasms: A Single Arm, Multicenter, Open-Label, Phase I/Ib Study. Blood 2023; 142 (Supplement 1): 1829.
[2] Zhao, Yanmin; Tu, Lifan; Luo, Yi; et al. S246: JAK/Rock Inhibitor TQ05105 for glucocorticoid-refractory or -dependent chronic graft-versus-host disease: updated results of a phase Ib/II study. HemaSphere 7(S3):p e9063756, August 2023.
[3] Á×Ëá«¿ÉÌæÄáƬ£¨JXHS1500114-19£©ËµÃ÷Êé, ¹ú¼ÒÒ©Æ·¼àÊÓÖÎÀí¾ÖÒ©Æ·ÉóÆÀÖÐÐÄ.
ÉùÃ÷£º
1. ±¾ÐÂΟåÖ¼ÔÚÔö½øÒ½Ò©ÐÅÏ¢µÄÏàͬºÍ½»Á÷£¬ £¬£¬£¬£¬½ö¹©Ò½ÁÆÎÀÉúרҵÈËÊ¿²ÎÔÄ£¬ £¬£¬£¬£¬·Ç¹ã¸æÓÃ;¡£¡£¡£ ¡£¡£
2. ±¾¹«Ë¾²î³ØÈκÎÒ©Æ·ºÍ/»ò˳Ӧ֢×÷ÍƼö¡£¡£¡£ ¡£¡£
3. ±¾ÐÂΟåÖÐÉæ¼°µÄÐÅÏ¢½ö¹©²Î¿¼£¬ £¬£¬£¬£¬²»¿ÉÒÔÈκη½·¨È¡´úרҵµÄÒ½ÁÆÖ¸µ¼£¬ £¬£¬£¬£¬Ò²²»Ó¦±»ÊÓΪÕïÁƽ¨Òé¡£¡£¡£ ¡£¡£ÈôÄúÏëÏàʶÏêϸ¼²²¡ÕïÁÆÐÅÏ¢£¬ £¬£¬£¬£¬Çë×ñ´ÓÒ½Éú»òÆäËûÒ½ÁÆÎÀÉúרҵÈËÊ¿µÄÒâ¼û»òÖ¸µ¼¡£¡£¡£ ¡£¡£